News

  • Jul 5, 2010

    Circadin® approved in the EU for treatment of Primary Insomnia in patients aged 55 or over for up to 3 months (Read more)

  • Apr 22, 2010

    EMEA approves Circadin® use for up to 3 months

  • Jun 11, 2009

    Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin® for Insomnia in Elderly Patients (Read more)

  • Sep 24, 2007

    Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck

  • Jul 6, 2007

    Nycomed to market Circadin® for primary insomnia (Read more)

  • Jun 29, 2007

    An Authorisation valid throughout the European Union was issued by the EMEA for Circadin®

  • Apr 27, 2007

    Neurim Pharmaceuticals announce that Circadin® for Primary Insomnia is recommended for approval in the EU (Read more)

  • Apr 26, 2007

    Summary of positive opinion for Circadin® (EMEA Press Release) (Read more)

  • News & Views

    • Dr. Zach Pearl

      Circadin.com Staff

    • December, 2018
    • Sleep and Dementia

    • Read More
Circadin